Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Works by KANG, JAHOON
Results: 10
1
2
982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-982-P
- By:
- Publication type:
- Article
3
53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-53-OR
- By:
- Publication type:
- Article
4
1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1023-P
- By:
- Publication type:
- Article
5
1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1014-P
- By:
- Publication type:
- Article
6
1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1001-P
- By:
- Publication type:
- Article
7
A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial.
- Published in:
- International Journal of Cancer, 2018, v. 143, n. 12, p. 3240, doi. 10.1002/ijc.31651
- By:
- Publication type:
- Article
8
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1292, doi. 10.1111/dom.14032
- By:
- Publication type:
- Article
9
Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1176, doi. 10.1111/dom.14020
- By:
- Publication type:
- Article
10
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2429, doi. 10.1111/dom.13824
- By:
- Publication type:
- Article